REC604b-Novel Adjuvanted Recombinant HPV 9-valent vaccine

Based on existing studies, compared to Merck’s Gardasil, GSK’s AS04-adjuvanted Cervarix has demonstrated strong cross-protection effectiveness with higher titers of neutralizing antibodies in clinical trials, suggesting that novel adjuvants can enhance the immunogenicity of HPV vaccines. Formulated with Novel AdjuvantSupported by our strong technology platforms, we are exploring opportunities to develop Recombinant HPV-9 vaccines formulated with novel adjuvant，they are designed to adopt a two-shot regimen. The project is currently in the preclinical research stage.